Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.

NCT07739654 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Interventions

DRUG: Cisplatin (modified schedule)
DRUG: Cisplatin
DRUG: Dexametasone
DRUG: Cytarabine (Ara-C)
DRUG: Cytarabine (Ara-C) (Modified schedule)

Sponsor

King Edward Medical University